User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

Primary tabs

Van Der Heijde, D. Klareskog, L. Landewé, R. Bruyn, G.A.W. Cantagrel, A. Durez, Patrick [UCL] Fatenejad, S.

Objective. The Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) is a 3-year, double-blind, multicenter study evaluating the efficacy and safety of etanercept, methotrexate, and the combination of etanercept plus methotrexate in patients with active rheumatoid arthritis (RA). The results after 1 and 2 years of the study have been previously reported. Here we provide the 3-year clinical and radiographic outcomes and safety of etanercept, methotrexate, and the combination in patients with RA. Methods. In this randomized, double-blind, multicenter TEMPO study, 682 patients received etanercept 25 mg twice weekly, methotrexate ≤20 mg weekly, or the combination. Key efficacy assessments included the Disease Activity Score (DAS) and the DAS in 28 joints. Results. Combination therapy resulted in significantly greater improvement in the DAS and in more patients with disease in remission than either monotherapy. This finding was confirmed by longitudinal analysis; patients receiving combination therapy were more than twice as likely to have disease in remission than those receiving either monotherapy. Independent predictors of remission included male sex, lower disease activity, lower level of joint destruction, and/or better physical function. Combination and etanercept therapy both resulted in significantly less radiographic progression than did methotrexate (P < 0.05). Etanercept and combination treatment were well tolerated, with no new safety findings. Conclusion. Etanercept plus methotrexate showed sustained efficacy through 3 years and remained more effective than either monotherapy, even after adjustment for patient withdrawal. Combination therapy for 3 years led to disease remission and inhibition of radiographic progression, 2 key goals for treatment of patients with RA. © 2007, American College of Rheumatology.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2007
Language Anglais
Journal information "Arthritis & Rheumatism" - Vol. 56, no. 12, p. 3928-3939 (2007)
Peer reviewed yes
Publisher John Wiley & Sons, Inc.
e-issn 1529-0131
issn 0004-3591
Publication status Publié
Affiliations UCL - (SLuc) Service de rhumatologie
UCL - MD/MINT - Département de médecine interne
Links
  1. Moreland Larry W., Etanercept Therapy in Rheumatoid Arthritis : A Randomized, Controlled Trial, 10.7326/0003-4819-130-6-199903160-00004
  2. Klareskog, Lancet, 363, 675 (2004)
  3. Van der Heijde, Arthritis Rheum, 54, 1063 (2006)
  4. Maini, Lancet, 354, 1932 (1999)
  5. Weinblatt, Arthritis Rheum, 48, 35 (2003)
  6. Weinblatt, N Engl J Med, 340, 253 (1999)
  7. Bathon, N Engl J Med, 343, 1586 (2000)
  8. Breedveld, Arthritis Rheum, 54, 26 (2006)
  9. St.Clair, Arthritis Rheum, 50, 3432 (2004)
  10. Landewe, Ann Rheum Dis, 61, 479 (2002)
  11. Twisk, Int J Sports Med, 18, S216 (1997)
  12. Zeger, Biometrics, 42, 121 (1986)
  13. Hedeker, Psychol Methods, 2, 64 (1997)
  14. Hochberg, Arthritis Rheum, 35, 498 (1992)
  15. Van der Heijde, J Rheumatol, 20, 579 (1993)
  16. Van Gestel, Arthritis Rheum, 41, 1845 (1998)
  17. Felson David T., Anderson Jennifer J., Lange Mary L. M., Wells George, LaValley Michael P., Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?, 10.1002/1529-0131(199809)41:9<1564::aid-art6>3.0.co;2-m
  18. Felson, Arthritis Rheum, 38, 727 (1995)
  19. Felson, Arthritis Rheum, 36, 729 (1993)
  20. Van der Heijde, Lancet, 1, 1036 (1989)
  21. Landewe, Arthritis Rheum, 50, 699 (2004)
  22. Van der Heijde D, Klareskog L, Baker P, Wajdula J, Fatenejad S. Etanercept combined with methotrexate is well tolerated for 3 years: results from the trial of etanercept and methotrexate with radiographic and patient outcomes (TEMPO). Poster number SAT0196. Presented at the Annual European Congress of Rheumatology, June 21-24, 2006, Amsterdam, The Netherlands.
  23. Fries, Arthritis Rheum, 23, 137 (1980)
  24. Van der Heijde, Ann Rheum Dis, 64, 1582 (2005)
  25. Landewe, Arthritis Rheum, 54, 3119 (2006)
Bibliographic reference Van Der Heijde, D. ; Klareskog, L. ; Landewé, R. ; Bruyn, G.A.W. ; Cantagrel, A. ; et. al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. In: Arthritis & Rheumatism, Vol. 56, no. 12, p. 3928-3939 (2007)
Permanent URL http://hdl.handle.net/2078.1/164706